# US 2021/0332046 A1 · Nicotinic acetylcholine receptor silent agonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0332046 A1
- Document ID: US20210332046A1
- Status: Published application
- Kind: A1
- Application number: 17/370,634
- Filed: 2021-07-08
- Published: 2021-10-28
- Earliest claimed: 2015-10-15
- Applicants: University of Florida Research Foundation, Inc.
- Inventors: Nicole Alana Horenstein; Roger Lee Papke; Marta Quadri
- Web page: https://patentgrep.com/patent/US20210332046A1

## CPC

- C07D 471/10: Spiro-condensed systems
- A61K 31/42: Oxazoles
- A61K 31/452: Piperidinium derivatives (pancuronium A61K31/58)
- A61K 31/495: having six-membered rings with two {or more} nitrogen atoms as the only ring heteroatoms, e.g. piperazine {or tetrazines}(A61K31/48 takes precedence {; with three nitrogen atoms A61K31/53})
- A61K 31/499: Spiro-condensed pyrazines or piperazines
- C07D 211/58: attached in position 4
- C07D 211/70: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 295/037: with quaternary ring nitrogen atoms
- C07D 295/073: with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/096: with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D 295/155: with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Derivatives of N,N-diethyl-N′-phenyl-piperazine, a silent agonist of the mammalian α7 nicotinic acetylcholine receptor, are provided. These silent agonists control the desensitization state of the receptor. Further provided are pharmaceutical compositions that allow the administration of the silent agonists of the disclosure to a subject animal or human in need of treatment for a pathological condition arising from such as inflammation. The novel silent agonists also may be co-administered to a patient simultaneously or consecutively with a type II positive allosteric modulator to modulate the activity of the receptor.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A compound having the formula III, or IV:
or a pharmaceutically acceptable salt thereof, wherein:
Y is:
Z is
n is 2, 3, 4, or 5;
R1, R2, and R3 is each independently a hydrogen, an alkyl group, cyano, an alkoxy group, a halogen, a trihaloalkyl, a carboxamide, pentafluorosulfanyl, or hydroxyl, and wherein the halogen is fluorine, chlorine or bromine; and
R5 is a hydrogen or a carboxytrifluoromethyl.

### Claim 22 (depends on 21)

The compound of claim 21, wherein R1, R2, and R3 is each independently a hydrogen, a methyl, cyano, methoxy, a halogen, trihaloalkyl, a carboxamide, pentafluorosulfanyl, or hydroxyl.

### Claim 23 (depends on 21)

The compound of claim 21, wherein R1, R2, and R3 is each independently a hydrogen, a methyl, cyano, methoxy, a halogen, a trihaloalkyl, a carboxamide, pentafluorosulfanyl, or hydroxyl, and R5 is hydrogen.

### Claim 24 (depends on 21)

The compound of claim 21, wherein:
when R1 is a methyl or a CN, R2 and R3 are each hydrogen;
when R1 is a methoxy, R2 is hydrogen R3 is hydrogen or methoxy;
when R1 is a halogen, R2 and R3 are each hydrogen;
when R1 is a trifluoromethyl, R2 and R3 are each hydrogen;
when R1 is a carboxamide, pentafluorosulfanyl, R2 and R3 are each hydrogen;
when R1 and R3 are each hydrogen, R2 is a methyl, a CN, a methoxy, a halogen, a trifluoromethyl, or a carboxamide, or OH; and
when R1 and R2 are each hydrogen, R3 is a methyl or Cl.

### Claim 25

A pharmaceutical composition comprising a compound having the formula III, or IV:
or a pharmaceutically acceptable salt thereof, wherein:
Y is:
Z is
n is 2, 3, 4, or 5;
R1, R2, and R3 is each independently a hydrogen, an alkyl group, cyano, an alkoxy group, a halogen, a trihaloalkyl, a carboxamide, pentafluorosulfanyl, or hydroxyl, and wherein the halogen is fluorine, chlorine or bromine;
R4 is a hydrogen or an ethyl group; and
R5 is a hydrogen or a carboxytrifluoromethyl; and a pharmaceutically acceptable carrier.

### Claim 26 (depends on 25)

The pharmaceutical composition of claim 25, wherein R1, R2, and R3 is each independently a hydrogen, a methyl, cyano, methoxy, a halogen, trihaloalkyl, a carboxamide or hydroxyl.

### Claim 27 (depends on 25)

The pharmaceutical composition of claim 25, wherein R1, R2, and R3 is each independently a hydrogen, a methyl, cyano, methoxy, a halogen, a trihaloalkyl, a carboxamide, pentafluorosulfanyl, or hydroxyl, and R5 is hydrogen.

### Claim 28 (depends on 25)

The pharmaceutical composition of claim 25, wherein:
when R1 is a methyl or a CN, R2 and R3 are each hydrogen;
when R1 is a methoxy, R2 is hydrogen R3 is hydrogen or methoxy;
when R1 is a halogen, R2 and R3 are each hydrogen;
when R1 is a trifluoromethyl, R2 and R3 are each hydrogen;
when R1 is a carboxamide, pentafluorosulfanyl, R2 and R3 are each hydrogen;
when R1 and R3 are each hydrogen, R2 is a methyl, a CN, a methoxy, a halogen, a trifluoromethyl, or a carboxamide, or OH; and
when R1 and R2 are each hydrogen, R3 is a methyl or Cl.

### Claim 29 (depends on 6)

The pharmaceutical composition of claim 6, wherein said composition is formulated to deliver to a human or animal subject in need thereof, an amount of the compound therapeutically effective in modulating the activity of a nicotinic acetylcholine receptor in the recipient patient, and wherein the therapeutically effective amount is delivered as a single dose or as a series of doses.

### Claim 30 (depends on 25)

The pharmaceutical composition of claim 25, further comprising a therapeutically effective amount of a nicotinic acetylcholine receptor positive allosteric modulator (PAM).

### Claim 31 (depends on 30)

The composition of claim 30, wherein the nicotinic acetylcholine receptor positive allosteric modulator (PAM) is a type II PAM.

### Claim 32 (depends on 31)

The composition of claim 31, wherein the nicotinic acetylcholine receptor positive allosteric modulator (PAM) is the type II PAM 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea (PNU-120596).

### Claim 33

A method of modulating the activity of a nicotinic acetylcholine receptor in an animal or human subject by administering to said subject therapeutically effective doses of a silent agonist of the nicotinic acetylcholine receptor and a nicotinic acetylcholine receptor positive allosteric modulator (PAM).

### Claim 34 (depends on 33)

The method of claim 33, wherein the silent agonist of the nicotinic acetylcholine receptor and the nicotinic acetylcholine receptor positive allosteric modulator (PAM) are administered to the subject simultaneously or as consecutive doses.

### Claim 35 (depends on 33)

The method of claim 33, wherein the silent agonist of the nicotinic acetylcholine receptor is a compound having the formula I, II, III, or IV:
or a pharmaceutically acceptable salt thereof, wherein:
Y is:
Z is
n is 2, 3, 4, or 5;
R1, R2, and R3 is each independently a hydrogen, an alkyl group, cyano, an alkoxy group, a halogen, a trihaloalkyl, a carboxamide, pentafluorosulfanyl, or hydroxyl, and wherein the halogen is fluorine, chlorine or bromine; and
R5 is a hydrogen or a carboxytrifluoromethyl.

### Claim 36 (depends on 15)

The method of claim 15, wherein the nicotinic acetylcholine receptor positive allosteric modulator (PAM) is a type II PAM.

### Claim 37 (depends on 18)

The method of claim 18, wherein the nicotinic acetylcholine receptor positive allosteric modulator (PAM) is the type II PAM 1-(5-chloro-2,4-dimethoxyphenyl)-3-(5-methylisoxazol-3-yl)urea (PNU-120596).
